MedPath

Fudan University

Fudan University logo
🇨🇳China
Ownership
Private
Established
1905-01-01
Employees
1K
Market Cap
-
Website
http://www.fudan.edu.cn

Clinical Trials

1.1k

Active:46
Completed:195

Trial Phases

6 Phases

Early Phase 1:5
Phase 1:59
Phase 2:447
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (850 trials with phase data)• Click on a phase to view related trials

Phase 2
447 (52.6%)
Not Applicable
172 (20.2%)
Phase 3
132 (15.5%)
Phase 1
59 (6.9%)
Phase 4
35 (4.1%)
Early Phase 1
5 (0.6%)

Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis

Not Applicable
Completed
Conditions
FAPI PET
Colorectal Cancer
Peritoneal (Metastatic) Cancer
Interventions
Combination Product: Radiotherapy followed by chemotherapy
Drug: Chemotherapy (control)
First Posted Date
2025-07-23
Last Posted Date
2025-07-23
Lead Sponsor
Fudan University
Target Recruit Count
40
Registration Number
NCT07079462
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in Intercostal Nerve Blockade

Not Applicable
Not yet recruiting
Conditions
Intercostal Nerve Block
Pulmonary Ventilation
Anesthesia, Local
Breast Neoplasms
Surgical Procedures, Operative
Interventions
First Posted Date
2025-07-23
Last Posted Date
2025-07-23
Lead Sponsor
Fudan University
Target Recruit Count
72
Registration Number
NCT07079436

Transcutaneous Electrical Nerve Stimulation in Nerve-Sparing Radical Hysterectomy: Effects on Bladder Management and Quality of Life in Cervical Cancer

Not Applicable
Completed
Conditions
Cervical Cancer
Postoperative Bladder Dysfunction
Urinary Retention
Pelvic Floor Muscle Weakness
Lower Urinary Tract Symptoms
Recovery of Bladder Function
Improvement in Pelvic Floor Muscle Strength
Enhancement of Quality of Life
First Posted Date
2025-07-17
Last Posted Date
2025-07-17
Lead Sponsor
Fudan University
Target Recruit Count
78
Registration Number
NCT07070687
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Not Applicable
Not yet recruiting
Conditions
Intrahepatic Cholangiocarcinoma (Icc)
Interventions
First Posted Date
2025-07-17
Last Posted Date
2025-07-17
Lead Sponsor
Fudan University
Target Recruit Count
56
Registration Number
NCT07070700
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Recruiting
Conditions
Diffuse Large B-Cell Lymphoma
DLBCL
Interventions
Drug: POLA-R-CHP
First Posted Date
2025-07-17
Last Posted Date
2025-07-17
Lead Sponsor
Fudan University
Target Recruit Count
300
Registration Number
NCT07070648
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 212
  • Next

News

Bio-Thera's BAT4406F Achieves Early Trial Success in Rare Neurological Disorder NMOSD

Bio-Thera Solutions' BAT4406F, an ADCC-enhanced anti-CD20 monoclonal antibody, demonstrated statistically significant efficacy in treating neuromyelitis optica spectrum disorder (NMOSD) during interim analysis of its pivotal Phase II/III trial.

Singlera Genomics' GutSeer Assay Achieves 81.5% Sensitivity in Detecting Early-Stage Gastrointestinal Cancers

Singlera Genomics and Fudan University's Zhongshan Hospital published results from the GUIDE prospective cohort study in Molecular Cancer, demonstrating their GutSeer assay's ability to detect five major gastrointestinal cancers through a simple blood test.

Multimodal AI System Demonstrates Superior Survival Prediction for Hepatocellular Carcinoma Immunotherapy

A novel multimodal fusion (MMF) system combining CT imaging-based deep learning with clinical features achieved C-index values of 0.74 for overall survival and 0.69 for progression-free survival in predicting outcomes for unresectable hepatocellular carcinoma patients receiving immune checkpoint inhibitors.

Physical Activity in Childhood Linked to Better Mental Health and Cognitive Function in Adolescence

Finnish longitudinal study reveals children with higher physical fitness levels develop better cognitive abilities and experience lower rates of depression and stress as teenagers.

Phase 2 Trial Shows Promise: Serplulimab-HLX04 Combination Safe for Advanced Liver Cancer

A phase 2 trial demonstrates manageable safety profile of serplulimab combined with bevacizumab biosimilar HLX04 as first-line treatment for advanced hepatocellular carcinoma.

Mixed Results for Immunotherapy in Early Triple-Negative Breast Cancer

The NSABP B-59 trial showed that adding atezolizumab to neoadjuvant chemotherapy did not significantly improve event-free survival in stage II-III TNBC.

Wegovy Enters Chinese Market as Obesity Rates Rise

Wegovy, a weight-loss drug containing semaglutide, has been introduced in China, offering a new treatment option for the country's increasing obese population.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.